
    
      Objectives:

      The primary objective is to evaluate the safety of the AdhVN1203/04.H5 vaccine when
      administered intranasally in two doses with an interval of 28 days in healthy adults 19-49
      years of age.

      The secondary objective is to evaluated the immunogenicity of the AdhVN1203/04.H5 vaccine at
      three different doses (10e8, 10e9 and 10e10 viral particles) when administered intranasally
      in two doses with an interval of 28 days in healthy adults 19-49 years of age.
    
  